

# Marie-Claude Bourgeois-Daigneault

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6745827/publications.pdf>

Version: 2024-02-01

28  
papers

1,785  
citations

586496

16  
h-index

651938

25  
g-index

28  
all docs

28  
docs citations

28  
times ranked

3692  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade. <i>Journal of Clinical Investigation</i> , 2018, 128, 4654-4668.                                 | 3.9 | 591       |
| 2  | Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy. <i>Science Translational Medicine</i> , 2018, 10, . | 5.8 | 242       |
| 3  | Interleukin-10-induced MARCH1 mediates intracellular sequestration of MHC class II in monocytes. <i>European Journal of Immunology</i> , 2008, 38, 1225-1230.               | 1.6 | 135       |
| 4  | Targeting the MHC Class II antigen presentation pathway in cancer immunotherapy. <i>Oncolmmunology</i> , 2012, 1, 908-916.  | 2.1 | 135       |
| 5  | VEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection. <i>Cancer Cell</i> , 2015, 28, 210-224.                    | 7.7 | 77        |
| 6  | Combination of Paclitaxel and MG1 oncolytic virus as a successful strategy for breast cancer treatment. <i>Breast Cancer Research</i> , 2016, 18, 83.                       | 2.2 | 73        |
| 7  | Oncolytic vesicular stomatitis virus expressing interferon- $\beta$ has enhanced therapeutic activity. <i>Molecular Therapy - Oncolytics</i> , 2016, 3, 16001.              | 2.0 | 63        |
| 8  | Sorting of MHC Class II Molecules into Exosomes through a Ubiquitin-Independent Pathway. <i>Traffic</i> , 2009, 10, 1518-1527.  | 1.3 | 61        |
| 9  | Oncolytic measles virus encoding interleukin-12 mediates potent antitumor effects through T cell activation. <i>Oncolmmunology</i> , 2017, 6, e1285992.                     | 2.1 | 60        |
| 10 | Amplification of Oncolytic Vaccinia Virus Widespread Tumor Cell Killing by Sunitinib through Multiple Mechanisms. <i>Cancer Research</i> , 2018, 78, 922-937.               | 0.4 | 46        |
| 11 | Autoregulation of MARCH1 Expression by Dimerization and Autoubiquitination. <i>Journal of Immunology</i> , 2012, 188, 4959-4970.  | 0.4 | 41        |
| 12 | Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination. <i>Nature Communications</i> , 2021, 12, 2626.   | 5.8 | 32        |
| 13 | MARCH1 E3 Ubiquitin Ligase Dampens the Innate Inflammatory Response by Modulating Monocyte Functions in Mice. <i>Journal of Immunology</i> , 2017, 198, 852-861.            | 0.4 | 29        |
| 14 | Taking a Stab at Cancer; Oncolytic Virus-Mediated Anti-Cancer Vaccination Strategies. <i>Biomedicines</i> , 2017, 5, 3.   | 1.4 | 29        |
| 15 | In silico trials predict that combination strategies for enhancing vesicular stomatitis oncolytic virus are determined by tumor aggressivity. , 2021, 9, e001387.           |     | 26        |
| 16 | Pre-surgical neoadjuvant oncolytic virotherapy confers protection against rechallenge in a murine model of breast cancer. <i>Scientific Reports</i> , 2019, 9, 1865.        | 1.6 | 21        |
| 17 | The pros and cons of interferons for oncolytic virotherapy. <i>Cytokine and Growth Factor Reviews</i> , 2020, 56, 49-58.  | 3.2 | 19        |
| 18 | Cutting Edge: HLA-DO Impairs the Incorporation of HLA-DM into Exosomes. <i>Journal of Immunology</i> , 2011, 187, 1547-1551.  | 0.4 | 18        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Brief Communication; A Heterologous Oncolytic Bacteria-Virus Prime-Boost Approach for Anticancer Vaccination in Mice. <i>Journal of Immunotherapy</i> , 2018, 41, 125-129.   | 1.2 | 16        |
| 20 | Tollip-induced down-regulation of MARCH1. <i>Results in Immunology</i> , 2013, 3, 17-25.   | 2.2 | 13        |
| 21 | Identification of a novel motif that affects the conformation and activity of the MARCH1 E3 ubiquitin ligase. <i>Journal of Cell Science</i> , 2013, 126, 989-98.  | 1.2 | 11        |
| 22 | Complement inhibition enables tumor delivery of LCMV glycoprotein pseudotyped viruses in the presence of antiviral antibodies. <i>Molecular Therapy - Oncolytics</i> , 2016, 3, 16027.   | 2.0 | 11        |
| 23 | Murine Tumor Models for Oncolytic Rhabdo-Virotherapy. <i>ILAR Journal</i> , 2016, 57, 73-85.   | 1.8 | 10        |
| 24 | Magnetic targeting of oncolytic VSV-based therapies improves infection of tumor cells in the presence of virus-specific neutralizing antibodies in vitro. <i>Biochemical and Biophysical Research Communications</i> , 2020, 526, 641-646.                           | 1.0 | 9         |
| 25 | Enhanced susceptibility of cancer cells to oncolytic rhabdo-virotherapy by expression of Nodamura virus protein B2 as a suppressor of RNA interference. , 2018, 6, 62.   |     | 8         |
| 26 | Major histocompatibility complex class-II molecules promote targeting of human immunodeficiency virus type 1 virions in late endosomes by enhancing internalization of nascent particles from the plasma membrane. <i>Cellular Microbiology</i> , 2013, 15, 809-822. | 1.1 | 5         |
| 27 | Pre-surgical oncolytic virotherapy improves breast cancer outcomes. <i>Oncolmmunology</i> , 2019, 8, e1655363.   | 2.1 | 4         |
| 28 | Oncolytic viruses for antigen delivery. , 2022, , 1-19.  |     | 0         |